Dr. Stéphane Epelbaum is a board-certified neurologist witha PhD in neuroscience. He played a pivotal role in shifting the concept of Alzheimer’s disease (AD) from unspecific dementia to a precise clinical-biological entity. He has participated in over 30 clinical trials including Aramis Lab, a brain data science lab. Dr. Epelbaum has authored over 100 articles on Alzheimer’s disease and related disorders, emphasizing timely and accurate diagnosis and innovative therapeutic options.
As a member of the International Working Group, Dr. Epelbaum notably contributed to the guidelines and co-authored a consensus article on preclinical Alzheimer’s disease with the National Institute on Aging and Alzheimer Association. In 2018, he was honored with the French Foundation Alzheimer's Prize for his outstanding clinical research. Since 2021, he has led the medical affairs neurology team in the international business unit of Eli Lilly and Company, focusing on closing clinical care gaps in neurological disorders.
